Graham Capital Management L.P. Invests $321,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Graham Capital Management L.P. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 37,577 shares of the biopharmaceutical company’s stock, valued at approximately $321,000.

Other hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. acquired a new stake in Ocular Therapeutix during the 4th quarter worth about $1,722,000. Charles Schwab Investment Management Inc. boosted its position in shares of Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after purchasing an additional 21,025 shares in the last quarter. Barclays PLC increased its holdings in Ocular Therapeutix by 37.1% in the third quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company’s stock worth $4,451,000 after purchasing an additional 138,441 shares in the last quarter. RoundAngle Advisors LLC bought a new stake in Ocular Therapeutix in the fourth quarter worth approximately $1,695,000. Finally, Tower Research Capital LLC TRC lifted its stake in Ocular Therapeutix by 2,045.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 8,446 shares during the period. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Stock Up 0.7%

Shares of NASDAQ OCUL opened at $7.22 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The company has a 50-day moving average price of $7.41 and a 200-day moving average price of $8.13. The stock has a market capitalization of $1.15 billion, a P/E ratio of -5.47 and a beta of 1.51. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

OCUL has been the subject of several recent analyst reports. Needham & Company LLC reduced their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. William Blair assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Royal Bank of Canada initiated coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, JMP Securities set a $19.00 price target on Ocular Therapeutix in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.25.

Insider Activity at Ocular Therapeutix

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard L. Md Lindstrom bought 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, May 8th. The stock was purchased at an average price of $6.96 per share, with a total value of $69,600.00. Following the purchase, the director now owns 172,704 shares in the company, valued at approximately $1,202,019.84. This represents a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. 2.30% of the stock is owned by insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.